Mesenchymal Stem Cells for the Treatment of Pneumonia Post Haematopoietic Stem Cell Transplantation

Completed

• Conditions: Hematopoietic Stem Cell Transplantation; Pneumonia

• Registration Number: NCT05131412
• Lead Sponsor: Guangzhou Women and Children's Medical Center

Brief Summary

The aim of this study is to determine whether mesenchymal stromal cell (MSC) treatment contribute to the good prognosis in patients with transplant-related complication, pneumonia post hematopoietic stem cell transplantation (HSCT).

Detailed Description

Hematopoietic stem cell transplantation (HSCT) is a standard therapy strategy for most hematologic disorders and malignancies. Despite the improved survival attributed to advances in HSCT including transplantation techniques and supportive care, transplant-related pneumonia (severe pneumonia in particular) remains the leading cause of death for most HSCT patients and a major challenge for clinicians.

Mesenchymal stromal cells (MSCs), a form of multipotent cells, have been applied in therapy for various intractable disorders. MSC exerts its therapeutic effect through various biological functions including immunoregulation, tissue repairing, self-renew and differentiating into various cell lines. The American Thoracic Society has also suggested MSCs as a cell therapy agent for lung diseases. However, MSC therapy for pneumonia following HSCT has not been well investigated.

By investigating the efficacy of MSC treatment for HSCT-related pneumonia via comparing the outcomes in patients with and without MSC treatment, this study will provide a promising therapy for HSCT-related pneumonia.

Study Timeline

• Study Start: 2018-08-08
• Primary Completion: 2021-01-01
• Study Completion: 2021-10-31
• Status Verified: 2021-11
• Study First Submitted: 2021-11-11
• Study First Submitted QC: 2021-11-11
• Last Update Submitted: 2021-11-22
• Study First Posted: 2021-11-23
• Last Update Posted: 2021-12-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 107

Inclusion Criteria

• patients with pneumonia after HSCT;
• patients under the age of 18 years;
• patients with normal pulmonary function before HSCT.

Exclusion Criteria

• patients with other severe complications in progress when pneumonia occurred.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall cure rate	12 months	the proportion of cured cases in all cases
time to cure	12 months	the time from the first diagnosis of pneumonia to a cure was achieved

Trial Locations

Locations (1)

Guangzhou Women and Children's Medical Center; 🇨🇳 Guangzhou, Guangdong, China